Table 6. Prognostic factors for OS of patients who underwent radical surgery.
|
Univariate
analysis |
Multivariate
analysis |
|||||
|---|---|---|---|---|---|---|
| Variable | No. of patients (n=67) (%) | MST (months) | P-value | HR | 95% CI | P-value |
| Gender | 0.8070 | |||||
| Male | 49 (73.1) | 76.0 | ||||
| Female | 18 (26.8) | — | 0.864 | 0.312–2.395 | 0.779 | |
| Location | 0.1022 | |||||
| Upper | 10 (14.9) | 76.0 | ||||
| Middle | 22 (32.8) | 63.5 | 0.503 | 0.111–2.289 | 0.374 | |
| Lower | 33 (49.2) | — | 0.473 | 0.114–1.963 | 0.303 | |
| Diffuse | 2(3.0) | 13.0 | 2.768 | 0.387–19.799 | 0.310 | |
| Pre-chemotherapy TNM | 0.0705 | 1.25 | 0.468–3.339 | 0.656 | ||
| IB | 5 (7.5) | — | ||||
| II | 49 (73.1) | — | ||||
| III | 13 (19.4) | 19.0 | ||||
| Lauren classification | 0.0036 | |||||
| Intestinal | 23 (34.3) | — | ||||
| Diffuse | 37 (55.2) | 38.0 | 9.963 | 1.937–51.235 | 0.006 | |
| Mixed | 7 (10.4) | 22.0 | 8.890 | 1.157–68.323 | 0.036 | |
| Local infiltration | 0.0214 | |||||
| Yes | 4 (6.0) | 16.2 | ||||
| No | 63 (94.0) | — | 0.584 | 0.141–2.416 | 0.458 | |
| Pathologic T downstaging | 0.3243 | |||||
| Yes | 22 (32.8) | — | ||||
| No | 45 (67.2) | 76.0 | 1.088 | 0.377–3.141 | 0.876 | |
| Pathologic N downstaging | 0.0171 | |||||
| Yes | 17 (25.4) | — | ||||
| No | 50 (74.6) | 54.0 | 6.532 | 0.088–3.220 | 0.492 | |
| ypTNM | <0.0001 | 4.045 | 1.429–11.446 | 0.008 | ||
| 0+I | 11 (16.4) | — | ||||
| II | 30 (44.7) | — | ||||
| III | 26 (38.8) | 17.5 | ||||
| Pathological evaluation standard of JCGC | 0.0292 | |||||
| G3+G2 | 20 (29.9) | — | ||||
| G1+G0 | 47 (70.1) | 76.0 | 1.127 | 0.321–3.955 | 0.852 | |
| Graded histologic response | 0.0364 | |||||
| ⩾50% | 33 (49.2) | — | ||||
| <50% | 34 (50.7) | 31.0 | 1.308 | 0.430–3.978 | 0.636 | |
Abbreviations: CI=confidence interval; HR=hazard ratio; JCGC=Japanese Gastric Cancer Association; MST=median survival time; OS=overall survival.